Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Two Japanese drug companies have signed R&D pacts with U.S. research institutes. Astellas Pharma will work with the University of Texas MD Anderson Cancer Center on a new treatment for patients with acute myeloid leukemia. The pact, which includes a payment of up to $26 million by Astellas, will focus on h8F4, a humanized monoclonal antibody invented by MD Anderson professor Jeffrey J. Molldrem. Daiichi Sankyo, meanwhile, will work with California’s Sanford-Burnham Medical Research Institute to develop a small-molecule cardiovascular-metabolic disease treatment that arose from work by a Sanford-Burnham scientist.
This article has been sent to the following recipient: